Repare Therapeutics (RPTX) director exits in $2.20 cash-and-CVR deal
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Repare Therapeutics director Carol Schafer has exited her position in the company through a cash-and-rights buyout. On January 28, 2026, she disposed of 8,000 common shares and had 37,941 stock options cancelled under an Arrangement Agreement involving XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation.
Each common share was exchanged for $2.20 in cash plus one contingent value right (CVR). Each option was cancelled in return for $2.20 minus its exercise price per underlying share, plus one CVR per underlying share, effectively cashing out her remaining equity in connection with the acquisition of all Repare common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
SCHAFER CAROL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 37,941 | $0.00 | -- |
| Disposition | Common Shares | 8,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 0 shares (Direct);
Common Shares — 0 shares (Direct)
Footnotes (1)
- Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share. Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share. This option was cancelled pursuant to the Arrangement Agreement in exchange for (i) $2.20 less the applicable exercise price in respect of such option plus (ii) one CVR per share underlying such option.
FAQ
What insider transaction did Repare Therapeutics (RPTX) director Carol Schafer report?
Carol Schafer reported disposing of all her Repare Therapeutics equity. She transferred 8,000 common shares and had 37,941 stock options cancelled on January 28, 2026, as part of a cash-and-CVR acquisition of all company common shares.
How were Carol Schafer’s Repare Therapeutics (RPTX) stock options treated?
Her 37,941 stock options were cancelled under the Arrangement Agreement. For each underlying share, she became entitled to $2.20 minus the option’s exercise price, plus one CVR, giving cash and contingent value in place of the previously held options.
Who acquired Repare Therapeutics (RPTX) in connection with Carol Schafer’s Form 4 transaction?
All issued and outstanding Repare Therapeutics common shares were acquired by Xeno Acquisition Corp. This was done under an Arrangement Agreement among Repare, XenoTherapeutics, Inc. as parent, Xeno Acquisition Corp. as purchaser, and XOMA Royalty Corporation.
What is the effective transaction date for Carol Schafer’s Repare Therapeutics (RPTX) equity exit?
The effective transaction date is January 28, 2026. On that date, her 8,000 common shares were exchanged and 37,941 stock options were cancelled in return for $2.20 cash per share terms plus contingent value rights under the acquisition agreement.
What consideration did Repare Therapeutics (RPTX) optionholders receive when options were cancelled?
Optionholders received $2.20 less the applicable exercise price for each option’s underlying share, plus one CVR per underlying share. This structure converted their option value into immediate cash plus a contingent value component tied to future outcomes.